New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 3, 2013
19:12 EDTSGMOSangamo BioSciences upgraded to Overweight from Underweight at Piper Jaffray
Piper Jaffray upgraded Sangamo BioSciences two notches to Overweight from Underweight and raised its price target for shares to $10 from $4 after assuming coverage of the stock. Piper says the company has a broad gene therapy platform with increasing visibility.
News For SGMO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 7, 2015
07:34 EDTSGMOAlliance for Regenerative Medicine to hold a meeting
Stem Cell Meeting on the Mesa is being held in La Jolla, California on October 7-9.
October 5, 2015
10:19 EDTSGMOSpark trial success a positive for gene therapy sector, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer said he views the news that Spark Therapeutics (ONCE) "highly anticipated" SPK-RPE65 Phase 3 gene therapy study for congenital blindness met its primary endpoint as a positive for the ophthalmology gene therapy field as well as the broader gene therapy sector. Schimmer added that Applied Genetic Technologies' (AGTC) early clinical data in the second half of this year will be a further test of the ophthalmology gene therapy platform. The analyst noted that other companies with gene therapy programs include Avalanche (AAVL), Biogen (BIIB), bluebird bio (BLUE), BioMarin (BMRN), Cellectis (CLLS), Medgenics (MDGN), uniQure (QURE), Pfizer (PFE), Regeneron (REGN) and Sangamo (SGMO).

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use